Drug Profile

Penpulimab - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group

Alternative Names: AK 105 - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group; Anniko

Latest Information Update: 04 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Akeso Biopharma
Developer Akeso Biopharma; Beijing Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group; Fudan University
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Programmed cell death 1 receptor antagonists; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Nasopharyngeal cancer
New Molecular Entity Yes

Marketed Hodgkin's disease; Nasopharyngeal cancer; Non-small cell lung cancer
Preregistration Liver cancer
Phase II Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer
Phase I/II Mesothelioma; Oesophageal cancer; Thymoma; Uterine cancer

04 Jun 2025 Chia Tai Tianqing Pharmaceutical Group terminates a phase-Ib trial in Liver cancer (First-line therapy, Combination therapy, Late-stage disease) in China (IV) (NCT05975645) due to business reasons, but no safety and efficacy concerns
25 Apr 2025 Efficacy and adverse events data from a phase III trial in Nasopharyngeal carcinoma were presented at the 116^th Annual Meeting of the American Association for Cancer Research (AACR-2025)
24 Apr 2025 Registered for Nasopharyngeal cancer (Metastatic disease, Combination therapy, First-line therapy, Late-stage disease) in USA (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com